A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
暂无分享,去创建一个
Y. Hamamoto | J. Sakamoto | Y. Suehiro | Ryouichi Tsunedomi | S. Hazama | K. Oba | N. Okayama | Y. Fujita | H. Mishima | S. Yoshino | T. Yamasaki | S. Kanekiyo | Y. Inoue | Masaki Oka | M. Oka
[1] J. Sakamoto,et al. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study. , 2014, Anticancer research.
[2] M. Oka,et al. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI‐treated metastatic colorectal cancer in two prospective studies in Japan , 2013, Cancer science.
[3] M. Oka,et al. UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer. , 2013, Anticancer research.
[4] Á. Carracedo,et al. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens , 2012, Cancer Chemotherapy and Pharmacology.
[5] Y. Kakeji,et al. Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms , 2011, Cancer science.
[6] J. Sakamoto,et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. , 2011, Japanese journal of clinical oncology.
[7] A. Carrato,et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy , 2010, British Journal of Cancer.
[8] M. Oka,et al. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism , 2010, Cancer science.
[9] Soma Das,et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Federico Innocenti,et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Teruhiko Yoshida,et al. Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese , 2009, Drug Metabolism And Disposition.
[12] Henk-Jan Guchelaar,et al. Clinical and pharmacogenetic factors associated with irinotecan toxicity. , 2008, Cancer treatment reviews.
[13] Teruhiko Yoshida,et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.
[14] M. Narabayashi,et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer , 2007, Cancer Chemotherapy and Pharmacology.
[15] M. Narabayashi,et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer , 2006, Cancer science.
[16] Giuseppe Toffoli,et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Shin,et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Alex Sparreboom,et al. Pharmacogenetics of irinotecan metabolism and transport: an update. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[19] M. Rocchi,et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan‐based chemotherapy , 2006, Cancer.
[20] Y. Hinoda,et al. Association of interleukin-10 promoter single nucleotide polymorphisms -819 T/C and -592 A/C with aging. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.
[21] M. Ratain,et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes , 2005, Pharmacogenetics and genomics.
[22] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[23] Westone,et al. Home Page , 2004, 2022 2nd International Conference on Intelligent Cybernetics Technology & Applications (ICICyTA).
[24] Kazuo Komamura,et al. UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer , 2004, Clinical pharmacology and therapeutics.
[25] H. McLeod,et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. , 2004, Pharmacogenetics.
[26] Soma Das,et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Ando,et al. Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients , 2002, Japanese journal of cancer research : Gann.
[29] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.
[30] J Verweij,et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] J P Pignon,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[32] H. Saka,et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.
[33] C. Guillemette,et al. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. , 2000, Pharmacogenetics.
[34] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[35] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[36] J. Robert,et al. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. , 1996, Biochemical pharmacology.
[37] Josef Kittler,et al. Floating search methods in feature selection , 1994, Pattern Recognit. Lett..
[38] K. Hirayasu,et al. Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated Nal and SDS. , 1994, Nucleic acids research.
[39] H. Kuga,et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.